ChiCTR2600125519 版本V1.0 版本创建时间2026/05/27 17:27:57 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600125519 

最近更新日期:

Date of Last Refreshed on:

2026-05-27 17:25:23 

注册时间:

Date of Registration:

2026-05-27 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

外泌体特征性标志物用于胰腺疾病辅助诊断和预后监测的临床研究

Public title:

Clinical Research on Exosome Signature Biomarkers for Auxiliary Diagnosis and Prognosis Monitoring of Pancreatic Diseases

注册题目简写:

外泌体标志物与胰腺疾病诊疗

English Acronym:

Exosomal Biomarkers and the Diagnosis and Treatment of Pancreatic Diseases

研究课题的正式科学名称:

外泌体特征性标志物用于胰腺疾病辅助诊断和预后监测的临床研究

Scientific title:

Clinical Research on Exosome Signature Biomarkers for Auxiliary Diagnosis and Prognosis Monitoring of Pancreatic Diseases

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张洁心 

研究负责人:

张洁心 

Applicant:

Jiexin Zhang 

Study leader:

Jiexin Zhang 

申请注册联系人电话:

Applicant telephone:

+86 138 5188 1088

研究负责人电话:

Study leader's
telephone:

+86 25 6830 3458

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

jiexinzhang@njmu.edu.cn

研究负责人电子邮件:

Study leader's E-mail:

jiexinzhang@njmu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

南京市广州路300号

研究负责人通讯地址:

江苏省南京市广州路300号

Applicant address:

Guangzhou Road No.300, Nanjing

Study leader's address:

No. 300, Guangzhou Road, Nanjing City, Jiangsu Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

南京医科大学第一附属医院

Applicant's institution:

The first affiliated hospital with Nanjing Medical University

研究负责人所在单位:

江苏省人民医院(南京医科大学第一附属医院)

Affiliation of the Leader:

Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2025-SR-457

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

南京医科大学第一附属医院(江苏省人民医院)伦理委员会

Name of the ethic committee:

Ethics Committee of the First Affiliated Hospital with Nanjing Medical university

伦理委员会批准日期:

Date of approved by ethic committee:

2025-06-04 00:00:00

伦理委员会联系人:

王嘉楠

Contact Name of the ethic committee:

Wang JiaNan

伦理委员会联系地址:

江苏省南京市广州路300号

Contact Address of the ethic committee:

No. 300, Guangzhou Road, Nanjing City, Jiangsu Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 25 6830 6360

伦理委员会联系人邮箱:

Contact email of the ethic committee:

1096493017@qq.com

研究实施负责(组长)单位:

江苏省人民医院(南京医科大学第一附属医院)

Primary sponsor:

Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)

研究实施负责(组长)单位地址:

江苏省南京市广州路300号

Primary sponsor's address:

No. 300, Guangzhou Road, Nanjing City, Jiangsu Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏省

市(区县):

Country:

China

Province:

Jiangsu

City:

单位(医院):

江苏省人民医院(南京医科大学第一附属医院)

具体地址:

江苏省南京市广州路300号

Institution
hospital:

Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)

Address:

No. 300, Guangzhou Road, Nanjing City, Jiangsu Province

经费或物资来源:

江苏省卫健委重点项目

Source(s) of funding:

Key Projects of Jiangsu Provincial Health Commission

研究疾病:

胰腺癌,急性胰腺炎,慢性胰腺炎,胰腺常见良性占位疾病(胰腺囊肿等)。  

Target disease:

Pancreatic cancer, acute pancreatitis, chronic pancreatitis, and common benign pancreatic space-occupying lesions (e.g., pancreatic cysts).

研究疾病代码:

Target disease code:

研究类型:

观察性研究

Study type:

Observational study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

队列研究 

Study design:

Cohort study 

研究目的:

本研究旨在检测胰腺疾病患者的血浆外泌体多个特征性标志物的表达水平,探讨其用于胰腺疾病辅助诊断和预后监测的临床应用价值。  

Objectives of Study:

This study aims to detect the expression levels of multiple characteristic markers in plasma exosomes from patients with pancreatic diseases.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 年龄20-90岁; 2. 胰腺癌患者:在我院确诊为胰腺癌(病理或影像学)的患者。 3. 胰腺良性疾病患者:急性胰腺炎,慢性胰腺炎,胰腺常见良性占位疾病(胰腺囊肿等)。

Inclusion criteria

1.Age between 20 and 90 years;
2.Pancreatic cancer patients: individuals diagnosed with pancreatic cancer at our institution based on histopathology or imaging findings;
3.Patients with benign pancreatic diseases: including acute pancreatitis, chronic pancreatitis, and common benign pancreatic space-occupying lesions (e.g., pancreatic cysts).

排除标准:

1.良性疾病组中急慢性胰腺炎病例在研究期间发展为胰腺癌者;既往有肿瘤病史者。

Exclusion criteria:

1.Patients initially enrolled in the benign disease group who are diagnosed with pancreatic cancer during the study period;
2.Individuals with a prior history of malignancy.

研究实施时间:

Study execute time:

From 2025-06-01 00:00:00 To 2027-05-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-06-01 00:00:00 To 2027-05-31 00:00:00

干预措施:

Interventions:

组别:

健康人

样本量:

300

Group:

Healthy control

Sample size:

干预措施:

干预措施代码:

Intervention:

None.

Intervention code:

组别:

胰腺癌

样本量:

300

Group:

Pancreatic cancer

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

组别:

胰腺良性疾病

样本量:

200

Group:

Benign pancreatic diseases

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏省 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

江苏省人民医院(南京医科大学第一附属医院) 

单位级别:

三级甲等 

Institution
hospital:

Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

外泌体标志物

指标类型:

主要指标

Outcome:

Exosomal Biomarker

Type:

Primary indicator

测量时间点:

手术前后

测量方法:

微量法

Measure time point of outcome:

pre-surgery and post-surgery

Measure method:

micro-method

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

NA

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age 90 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

Blinding:

None

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

无。

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None.

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表和电子数据管理系统。

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

?Clinical Data Sheet and Electronic Health Record System

数据与安全监察委员会:

Data and Safety Monitoring Committee:

无/No

注册人:

Name of Registration:

 2026-05-27 17:25:23